Expanding the use of T-DXd in metastatic HR-positive breast cancer: where are we now?
Nat Rev Clin Oncol
.
2025 Jan;22(1):6-7.
doi: 10.1038/s41571-024-00963-2.
Authors
Joshua Drago
1
2
,
Shanu Modi
3
4
Affiliations
1
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. dragoj@mskcc.org.
2
Weill Cornell Medical College, New York, NY, USA. dragoj@mskcc.org.
3
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
4
Weill Cornell Medical College, New York, NY, USA.
PMID:
39506069
DOI:
10.1038/s41571-024-00963-2
No abstract available